Passage Bio, Inc. announced the appointment of Michael Kamarck, Ph.D., to its board of directors and his appointment to the Nominating and Corporate Governance Committee. Dr. Kamarck is a seasoned biopharmaceutical executive with over forty years of experience in discovery research, process development and technical operations. Dr. Kamarck is the Chairman of the Sanofi Biotech Advisory Council, providing strategic guidance to advance Sanofi's biologicals business.

He recently retired as Chief Technology Officer for Vir Biotechnology, Inc., where he led a multi-modality technical approach to the development of treatments of serious infectious diseases such as COVID-19 (sotrovimab), influenza and hepatitis B. Prior to joining Vir, Dr. Kamarck was the Senior Vice President of Global Vaccines and Biologics Manufacturing and President of Merck BioVentures. In this role, he was responsible for the worldwide manufacturing network in support of the vaccine portfolio and biologics businesses. Dr. Kamarck also held numerous senior executive positions at Wyeth Pharmaceuticals, including President, Technical Operations and Product Supply as a member of the Wyeth Management Team.

While with Wyeth, he was responsible for establishing a global biotechnology network of more than 10,000 employees to develop and manufacture numerous blockbuster products, including building the manufacturing infrastructure to deliver the global supply of Prevnar 13® and Enbrel®. Dr. Kamarck also spent 16 years at Bayer AG serving in numerous roles, including Senior Vice President of Operations for Bayer Biologicals. He has authored more than 50 peer-reviewed publications and has 20 issued patents.

He currently serves on the board of directors of Vaxcyte, Inc. Dr. Kamarck holds a Ph.D. in biochemistry from the Massachusetts Institute of Technology and a bachelor's degree in biology from Oberlin College.